Q32 Bio reported that bempikibart (bempi) hit the Phase 2 main goal in alopecia areata, with two-fifths of patients reaching a hair-covering threshold after 36 weeks. Investors reacted strongly to the more conclusive part B results in severe or very severe alopecia areata, and the company positioned its IL-7R-alpha antibody approach as a potential alternative to JAK inhibitors. The readout is also fueling additional coverage around the broader Phase 2 strategy and the rationale for immune reset by blocking IL-7 and TSLP signaling—an approach intended to balance efficacy with the safety concerns seen in earlier JAK inhibitor risk discussions.